Table 1.
CD47-related clinical trials registered in US national clinical trials registry (NCT) system www.clinicaltrials.gov
| Agent | CD47 Isotype | Organization | Mechanism of action | NCT Number | Status | Conditions | Phase | Enrollment | Start dates |
|---|---|---|---|---|---|---|---|---|---|
| AK117 | IgG4 | Akesobio | A new generation of humanized anti-human CD47 IgG4 mAb, | NCT04349969 | Not yet recruiting | Neoplasms Malignant | Phase 1 | 159 | 25-Apr-20 |
| NCT04728334 | Recruiting | Neoplasms Malignant | Phase 1 | 162 | 27-Jan-21 | ||||
| NCT04900350 | Recruiting | MDS | Phase 1/2 | 190 | 18-Jun-21 | ||||
| NCT04980885 | Recruiting | AML | Phase 1/2 | 160 | Jul-21 | ||||
| AO-176 | IgG2 | Arch Oncology | Fully humanized anti-human CD47 monoclonal antibody | NCT03834948 | Recruiting | Solid Tumor | Phase 1/2 | 183 | 4-Feb-19 |
| NCT04445701 | Recruiting | MM | Phase 1/2 | 102 | 30-Nov-20 | ||||
| CC-90002 | IgG4 | Celgene | First generation anti-human CD47 antibody | NCT02367196 | Completed | Hematological Malignancies | Phase 1 | 60 | 12-Mar-15 |
| CPO107 JMT601 (CPO107) | IgG1 (CD20) | Conjupro Biotherapeutics, Inc | Bi-specific SIRP α and anti-CD20 fusion protein. Through interference of CD47/SIRP α interaction to enhance antibody-dependent phagocytosis (ADCP) | NCT04853329 | Not yet recruiting | NHL | Phase 1/2 | 75 | 15-Aug-21 |
| DSP107 | IgG4 | KAHR Medical | Bi-functional CD47 and 41BB fusion protein | NCT04440735 | Recruiting |
Advanced Solid Tumor Non-Small Cell Lung Cancer |
Phase 1 Phase 2 |
100 | 7-Oct-20 |
| NCT04937166 | Recruiting |
AML/MDS CML |
Phase 1 Phase 2 |
36 | Sep-21 | ||||
| Evorpacept (ALX148) | IgG1 | ALX Oncology | Fusion protein of SIRPα D1 domain and an inactive human IgG1 Fc | NCT03013218 | Active, not recruiting |
Solid Tumor NHL |
Phase 1 | 174 | 3-Feb-17 |
| NCT04417517 | Recruiting | MDS | Phase 1 | 173 | 2-Oct-20 | ||||
| NCT04675294 | Recruiting | Head and Neck Squamous Cell Carcinoma | Phase 2 | 111 | April 2, 2021 | ||||
| NCT04675333 | Recruiting | Head and Neck Squamous Cell Carcinoma | Phase 2 | 112 | 10-May-21 | ||||
| NCT04755244 | Recruiting | AML | Phase 1/2 | 97 | 5-May-21 | ||||
| NCT05002127 | Not yet recruiting |
Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma |
Phase 2/3 | 450 | Aug-21 | ||||
| Hu5F9-G4 Magrolimab(5F9) | IgG4 | Gilead Sciences/Forty Seven | Anti-human CD47 mAb | NCT02216409 | Completed | Solid Tumor | Phase 1 | 88 | Aug-14 |
| NCT02678338 | Completed | AML/MDS | Phase 1 | 20 | Nov-15 | ||||
| NCT03248479 | Recruiting | Hematological Malignancies | Phase 1 | 287 | 8-Sep-17 | ||||
| NCT03527147 | Completed |
NHL DLBCL NHL Diffuse Large B Cell Lymphoma |
Phase 1 | 30 | 19-Jun-18 | ||||
| NCT04599634 | Not yet recruiting |
Follicular Lymphoma Marginal Zone Lymphoma Mantle Cell Lymphoma Chronic Lymphocytic Lymphoma B-Cell Lymphoma |
Phase 1 | 76 | 1-Sep-21 | ||||
| HX009 | IgG4 | Hanxbio | PD-1/CD47 bi-specific mAb | NCT04097769 | Active, not recruiting | Advanced Solid Tumor | Phase 1 | 20 | 18-Mar-21 |
| NCT04886271 | Recruiting | Solid Tumor | Phase 2 | 210 | 10-May-21 | ||||
| IBI188 | IgG4 | Innovent Bio | Recombinant human anti-CD47 mAb | NCT03717103 | Active, not recruiting | Advanced Malignancies | Phase 1 | 49 | 10-Jan-19 |
| NCT03763149 | Active, not recruiting | Advanced Malignancies | Phase 1 | 42 | 11-Jan-19 | ||||
| NCT04485052 | Recruiting | AML |
Phase 1 Phase 2 |
126 | Apr-21 | ||||
| NCT04485065 | Recruiting | MDS | Phase 1 | 12 | 30-Sep-20 | ||||
| NCT04861948 | Recruiting |
Solid Tumors Lung Adenocarcinoma Osteosarcoma |
Phase 1 | 120 | 25-May-21 | ||||
| IBI322 | IgG4 | Innovent Bio | Bi-specific antibody that can target CD47 and PD-L1 | NCT04328831 | Recruiting | Advanced Malignancies | Phase 1 | 218 | 31-Jul-20 |
| NCT04338659 | Recruiting | Advanced Malignancies | Phase 1 | 45 | Apr-21 | ||||
| NCT04795128 | Recruiting | Hematological Malignancies | Phase 1 | 230 | 7-May-21 | ||||
| NCT04912466 | Recruiting | Solid Tumor | Phase 1 | 36 | 20-Jun-21 | ||||
| IMC-002 | IgG4 |
ImmuneOncia Therapeutics 3D Medicines |
Anti-human CD47 monoclonal antibody | NCT04306224 | Recruiting |
Solid Tumor NHL |
Phase 1 | 24 | 5-Jun-20 |
| IMM0306 | IgG1 | ImmneOnco | Bi-specific antibody targeting CD47 and CD20 at the same time | NCT04746131 | Not yet recruiting | NHL | Phase 1 | 90 | 15-Aug-21 |
| OSE-172 | IgG4 | OSE Immunotherapeutics | Humanized IgG4 mAb against SIRPα | NCT04806035 | Recruiting |
CLL SLL Richter's Transformation Indolent Lymphoma Follicular Lymphoma Marginal Zone Lymphoma Aggressive Lymphoma DLBCL Mediastinal Large B-cell Lymphoma MCL |
Phase 1 | 60 | 23-Apr-21 |
| PF-07257876 | IgG4 | Pfizer | Bi-specific antibody against CD47 and PD-L1, | NCT04881045 | Not yet recruiting |
Non-Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma Ovarian Cancer |
Phase 1 | 90 | 27-Aug-21 |
| SHR-1603 | IgG4 | Jiangsu HengRui Medicine | Humanized IgG4 mAb targeting CD47 | NCT03722186 | Suspended |
Physiological Effects of Drugs Neoplasms by Histologic Type NHL |
Phase 1 | 128 | 13-Nov-18 |
| SHR2150 | IgG4 (TLR7) | HengRui Pharma | Selective TLR7 receptor agonist | NCT04588324 | Recruiting | Solid Tumor | Phase 1/2 | 50 | 10-Oct-20 |
| SRF231 | IgG4 | Surface Oncology | Anti-human CD47 mAb | NCT03512340 | Completed |
Advanced Solid Cancers Hematological Malignancies |
Phase 1 | 148 | 13-Mar-18 |
| STI-6643 | IgG4 | Sorrento Therapeutics, Inc | Fully humanized anti-CD47 mAb | NCT04900519 | Not yet recruiting | Solid Tumor | Phase 1 | 24 | Aug-21 |
| TG-1801 | IgG4 |
Novimmune SA TG Therapeutics |
Bi-specific mAb targeting both CD19 and CD47 | NCT03804996 | Recruiting | NHL | Phase 1 | 16 | 5-Mar-19 |
| TJ011133 | IgG4 | I-MAB Biopharma | Highly differentiated CD47 monoclonal antibody | NCT04895410 | Not yet recruiting | MM | Phase 1 | 163 | 13-Jul-21 |
| NCT04912063 | Recruiting | AML/MDS | Phase 1 | 120 | 15-Jun-21 | ||||
| TTI-621 | IgG1 | Trillium Therapeutics Inc | SIRPα-IgG1 Fc, checkpoint inhibitor CD47 blocker, | NCT02663518 | Recruiting |
Hematological Malignancies Solid Tumor |
Phase 1 | 260 | Jan-16 |
| NCT04996004 | Recruiting | Leiomyosarcoma | Phase 1/2 | 80 | 25-Jun-21 | ||||
| ZL-1201 | IgG4 | Zai Lab | Anti-human CD47 mAb | NCT04257617 | Recruiting | Advanced Malignancies | Phase 1 | 66 | 11-May-20 |